DNA

GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease

Results from commercial sales of predictive testing across the US and Australia establish clear advantages of geneType Risk Assessment Tests…

2 years ago

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who…

2 years ago

SNL Creative and Iridia Announce Revolutionary Partnership to Enhance Medical Device Traceability; Showcasing at RAPID + TCT Show, Booth #2651

LOS ANGELES, June 25, 2024 (GLOBE NEWSWIRE) -- SNL Creative, a leader in additive manufacturing, and Iridia, a pioneer in…

2 years ago

Illumina completes the divestiture of GRAIL

GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25Illumina to issue second quarter 2024 results…

2 years ago

Thermal Cyclers Market Worth 1.86 Billion 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.

JERSEY CITY, N.J., June 24, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report…

2 years ago

Juniper Biologics Expands Distribution Rights for Caris Life Sciences’ Molecular Profiling in the Middle East and Africa

SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on…

2 years ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscapeDOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --…

2 years ago

Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27

CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic…

2 years ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of…

2 years ago